MONMOUTH JUNCTION, N.J., Nov. 12, 2018 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, and Chief Financial Officer, Ms. Kathleen Bloch, MBA, will separately present an overview of the company at multiple healthcare conferences this week.

CytoSorbents Logo. (PRNewsFoto/CytoSorbents)

In addition to the company presentations, Dr. Chan will meet with European investors in London, and Ms. Bloch will meet with predominantly U.S. investors in New York via one-on-one meetings on the day of the presentation.  Please contact the appropriate banking representative to be added to the one-on-one schedule.

Stifel 2018 Healthcare Conference – November 13, 2018
Who:          Ms. Kathleen Bloch – Chief Financial Officer, CytoSorbents Corporation
Where:       Lotte New York Palace Hotel – New York City
When:        Tuesday, November 13, 2018 at 5:00 PM EST
Webcast:    Stifel Presentation Webcast link

Jefferies 2018 London Healthcare Conference – November 14, 2018
Who:          Dr. Phillip Chan – Chief Executive Officer, CytoSorbents Corporation
Where:       Waldorf Hilton, Aldwych – London, England
When:        Wednesday, November 14, 2018 at 8:00 AM GMT
Webcast:    Jefferies Presentation Webcast link

Canaccord Genuity 2018 Medical Technologies & Diagnostics Forum – November 15, 2018
Who:          Ms. Kathleen Bloch – Chief Financial Officer, CytoSorbents Corporation
Where:       Westin Grand Central – New York City
When:        Thursday, November 15, 2018 at 1:00 PM EST
Webcast:    Canaccord Presentation Webcast link

A live webcast of the presentation will be available at the above webcast link.  An archived replay will be available on the Company’s website after the presentation.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 53 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.  CytoSorb® has been used in more than 51,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites at and  or follow us on Facebook and Twitter

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:
Amy Vogel

Investor Relations


Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors


Public Relations Contact:
Joshua Berkman

Rubenstein Public Relations



SOURCE CytoSorbents Corporation